Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

v3.20.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Operating expenses:    
Research and development $ 4,926,714 $ 1,488,839
General and administrative 7,855,220 4,378,897
Depreciation and amortization 21,015 7,935
Total operating expenses 12,802,949 5,875,671
Loss from operations (12,802,949) (5,875,671)
Other income (expense):    
Interest income, net 39,576 6,123
Gain on disposal of assets 0 0
Loss before income taxes (12,763,373) (5,869,548)
Income taxes (benefit) 0 0
Net loss (12,763,373) (5,869,548)
Preferred stock dividend (4,618) (10,541)
Net loss attributable to common stockholders (12,767,991) (5,880,089)
Non-controlling interest 1,427,813 0
NET LOSS ATTRIBUTABLE TO BIOSIG TECHNOLOGIES, INC. $ (11,340,178) $ (5,880,089)
Net loss per common share, basic and diluted (in Dollars per share) $ (0.46) $ (0.33)
Weighted average number of common shares outstanding, basic and diluted (in Shares) 24,389,249 17,848,238